|Articles|June 15, 2004
Topical cyclosporine can handle more than dry-eye disease
Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
What ‘I’m Fine’ Really Means: An Open Letter from a Thyroid Eye Disease (TED) Patient
2
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
3
From then to next: Five decades of transformation in ophthalmology
4
Q&A: Advancing a long-acting anti-VEGF candidate: What it means for retinal disease
5














































.png)


